Format

Send to

Choose Destination
Cancer Manag Res. 2018 Nov 8;10:5537-5544. doi: 10.2147/CMAR.S179767. eCollection 2018.

Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.

Author information

1
Department of Oncology/Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland, lukas.flatz@gmail.com, stefan.diem@kssg.ch.
2
Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland, lukas.flatz@gmail.com, stefan.diem@kssg.ch.
3
Department of Oncology/Haematology, Spital Grabs, St. Gallen, Switzerland, stefan.diem@kssg.ch.
4
Department of Dermatology, University Hospital Zürich, Zürich, Switzerland, lukas.flatz@gmail.com.
5
Clinical Trials Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland, lukas.flatz@gmail.com.
6
University of Bern, Bern, Switzerland.
7
Department of Dermatology/Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland, lukas.flatz@gmail.com.

Abstract

Background:

Prognosis of metastatic non-small cell lung cancer significantly improved with the availability of checkpoint inhibitors (anti-PD-1/PD-L1). Unfortunately, reliable biomarkers to predict treatment benefit are lacking.

Patients and methods:

We prospectively collected clinical and laboratory data of 56 non-small cell lung cancer patients treated with a checkpoint inhibitor. The aim was to identify baseline parameters correlating with worse outcome and to create a risk score that enabled to stratify patients into different risk groups. As inflammation is known to promote tumor growth, we focused on inflammation markers in the blood. Disease control (DC) was defined as complete response, partial response, and stable disease on CT scan according to RECIST 1.1.

Results:

Half of the patients achieved DC. Four parameters differed significantly between the DC group and the no disease control group: Eastern Cooperative Oncology Group performance status (P=0.009), number of organs with metastases (P=0.001), lactate dehydrogenase (P=0.029), and ferritin (P=0.005). A risk score defined as the number of these parameters (0= no risk factor) exceeding a threshold (Eastern Cooperative Oncology Group performance status ≥2, number of organs with metastases ≥4, lactate dehydrogenase ≥262U/L, and ferritin ≥241 µg/L) was associated with overall survival and progression-free survival. Overall survival at 6 and 12 months is as follows: Scores 0-1: 95% and 95%; Score 2: 67% and ≤33%; Scores 3-4: 15% and 0%. Progression-free survival at 6 and 12 months is as follows: Scores 0-1: 81% and 50%; Score 2: 25% and ≤25%; Scores 3-4: 0% and 0%.

Conclusion:

We propose an easy-to-apply risk score categorizing patients into different risk groups before treatment start with a PD-1/PD-L1 antibody.

KEYWORDS:

NSCLC; biomarkers; checkpoint inhibitor; response; risk score; survival

Conflict of interest statement

Disclosure MF received research support from BMS and AstraZeneca (not for this project); Honoraria to institution for advisory: MSD, Roche, Astra, BMS, Boehringer. The authors report no other conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center